Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19

NCT04373460 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT04373460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04373460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19
Lead sponsor
Johns Hopkins University
Phase
Phase 2
Overall status
Completed
Start date
June 3, 2020
Completion date
December 14, 2022
Enrollment
1,225 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov 2